Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...5455565758596061626364...7475»
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion, Enrollment change:  30g vs 33g Needle for Intravitreal Injections (clinicaltrials.gov) -  Jul 24, 2017   
    P=N/A,  N=50, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=100 --> 50
  • ||||||||||  Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion:  Phase II Combination Steroid and Anti-VEGF for Persistent DME (clinicaltrials.gov) -  Jul 12, 2017   
    P2,  N=129, Completed, 
    Recruiting --> Completed | N=100 --> 50 Recruiting --> Completed
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Enrollment change, Trial primary completion date:  OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov) -  May 30, 2017   
    P=N/A,  N=80, Recruiting, 
    Recruiting --> Active, not recruiting N=20 --> 80 | Trial primary completion date: Dec 2016 --> Dec 2018
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Trial completion:  Efficacy and Safety of Lucentis (clinicaltrials.gov) -  May 4, 2017   
    P4,  N=21, Completed, 
    Recruiting --> Active, not recruiting | N=150 --> 226 Active, not recruiting --> Completed
  • ||||||||||  DS-7080a / Daiichi Sankyo
    Trial primary completion date:  Study of DS-7080a for the Treatment of Macular Degeneration (clinicaltrials.gov) -  Apr 17, 2017   
    P1,  N=45, Active, not recruiting, 
    Phase classification: P4 --> P=N/A Trial primary completion date: Mar 2017 --> Mar 2018
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Trial completion, Trial primary completion date:  The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study (clinicaltrials.gov) -  Mar 31, 2017   
    P2,  N=126, Completed, 
    Trial primary completion date: Nov 2016 --> Apr 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2008 --> Aug 2010
  • ||||||||||  DS-7080a / Daiichi Sankyo
    Enrollment closed:  Study of DS-7080a for the Treatment of Macular Degeneration (clinicaltrials.gov) -  Mar 13, 2017   
    P1,  N=45, Active, not recruiting, 
    N=300 --> 230 | Trial primary completion date: Apr 2018 --> Dec 2017 Recruiting --> Active, not recruiting
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Biomarker, Trial primary completion date:  Ranibizumab Treatment for Retinal Vein Occlusion (clinicaltrials.gov) -  Mar 10, 2017   
    P=N/A,  N=100, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Sep 2019